Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy

Chest

Volumn 125, Issue 5, 2004, Pages 1642-1650

  Spyropoulos, Alex C ^a   Frost, Floyd J ^b   Hurley, Judith S ^b   Roberts, Melissa ^b  

^a Lovelace Sandia Health Systems   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Enoxaparin; Low molecular weight heparin; Managed care; Oral anticoagulant therapy; Outpatient treatment; Perioperative bridging; Pharmacoeconomic evaluation

Indexed keywords

ANESTHETIC AGENT; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTERY DISEASE; ARTICLE; BLEEDING; BRAIN DISEASE; CALCULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG USE; ELECTIVE SURGERY; FEMALE; GENERAL ANESTHESIA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH MAINTENANCE ORGANIZATION; HEALTH SERVICE; HEART DISEASE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAL RECORD; MEXICO; OPERATION DURATION; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; PATIENT CARE; PERIOPERATIVE PERIOD; PHARMACY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBUS; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; VALVULAR HEART DISEASE; VEIN DISEASE; VENOUS THROMBOEMBOLISM;

EID: 2442486457     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.5.1642     Document Type: Article

References (27)

1. Dunn AS, Turpie AGG. Perioperative management of patients receiving oral anticoagulants: a systemic review. Arch Intern Med 2003; 163:901-908
2. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves: a prospective study. Am Heart J 1978; 96:163-165
3. Tiede DJ, Nishimura RA, Gastineau DA, et al. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998; 73:665-680
4. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336:1506-1511
5. British Society for Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 1998; 101:374-387
6. Weibert RT. Oral anticoagulant therapy in patients undergoing dental surgery. Clin Pharm 1992; 11:857-864
7. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119(suppl):22S-38S
8. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114:545-551
9. Levine MN, Gent M, Hirsh J, et al. A comparison of low-molecular-weight- heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-681
10. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight-heparin with UFH for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447-452
11. Spandorfer JM, Lynch S, Weitz HH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84:478-480
12. Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: role of low-molecular-weight heparin (dalteparin). Thromb Haemost 1999; 82(suppl):62-63
13. Tinmouth AH, Morrow BH, Cruickshank MK, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001; 35:669-674
14. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000; 101:1083-1086
15. Nguyen DPN, Hasson NK. Perioperative management of patients on long-term warfarin therapy. Hosp Pharm 1999; 34:103-110
16. De Lissovoy G, Yusen RD, Spiro TE, et al. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Arch Intern Med 2000; 160:3160-3165
17. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight-heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130:789-799
18. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health Syst Pharm 1997; 54:1185-1190
19. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndromes: results from the ESSENCE randomized trial. Circulation 1998; 97:1702-1707
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-619
21. Groce JB III. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Pharmacotherapy 1998; 18:175S-180S
22. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000; 160:2926-2932
23. Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002; 122:108-114
24. Tsilimingras K, Grasso-Correnti N, Fanikos J, et al. Initiation of anticoagulation after cardiac surgery: a prospective cohort study of efficacy, safety, and cost with low-molecular-weight heparin bridging in lieu of continuous intravenous unfractionated heparin. J Am Coll Cardiol 2002; 39(suppl):836-837
25. Home low-molecular-weight heparin bridge therapy in cardiac replacement: safe, effective, and cost-saving. Formulary 2000; 35:990-991
26. Kovacs M, Kahn S, Solymoss S, et al. Prospective multicentre trial of bridging therapy with dalteparin for patients who require temporary discontinuation of OAC for prosthetic valves or high risk atrial fibrillation [abstract]. Blood 2002; 100:149a
27. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332:1330-1335